Lee Jung Soo, Kim Seoree, Sung Soo-Yoon, Kim Yeo Hyung, Lee Hyun Woo, Hong Ji Hyung, Ko Yoon Ho
Department of Rehabilitation Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Division of Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Front Oncol. 2021 Mar 22;11:546672. doi: 10.3389/fonc.2021.546672. eCollection 2021.
To investigate the efficacy of irinotecan-based (IP) and etoposide-based (EP) platinum combinations, and of single-agent chemotherapy, for treatment of extensive-disease small cell lung cancer (ED-SCLC), we performed a large-scale, retrospective, nationwide, cohort study. The population data were extracted from the Health Insurance Review and Assessment Service of Korea database from January 1, 2008, to November 30, 2016. A total of 9,994 patients were allocated to ED-SCLC and analyzed in this study. The primary objectives were to evaluate the survival outcomes of systemic first-line treatments for ED-SCLC. For first-line treatment, patients who received IP showed a better time to first subsequent therapy (TFST) of 8.9 months (95% confidence interval [CI], 8.50-9.40) than those who received EP, who had a TFST of 6.8 months (95% CI, 6.77-6.97, P < 0.0001). In terms of overall survival (OS), IP was superior to EP (median OS, 10.8 months; 95% CI, 10.13-11.33 vs. 9.5 months; 95% CI, 9.33-9.73; P < 0.0001). Taken together, in the Korean population, first-line IP combination chemotherapy had significantly favorable effects on OS and TFST.
为了研究以伊立替康为基础（IP）和以依托泊苷为基础（EP）的铂类联合化疗以及单药化疗治疗广泛期小细胞肺癌（ED-SCLC）的疗效，我们开展了一项大规模、回顾性、全国性队列研究。人口数据取自韩国健康保险审查与评估服务数据库，时间跨度为2008年1月1日至2016年11月30日。本研究共纳入9994例ED-SCLC患者并进行分析。主要目的是评估ED-SCLC全身一线治疗的生存结果。对于一线治疗，接受IP治疗的患者首次后续治疗时间（TFST）为8.9个月（95%置信区间[CI]，8.50-9.40），优于接受EP治疗的患者，后者的TFST为6.8个月（95%CI，6.77-6.97，P<0.0001）。在总生存期（OS）方面，IP也优于EP（中位OS，10.8个月；95%CI，10.13-11.33 vs. 9.5个月；95%CI，9.33-9.73；P<0.0001）。总体而言，在韩国人群中，一线IP联合化疗对OS和TFST有显著的有利影响。
